Society of Urologic Oncology position statement: redefining the management of hormone-refractory prostate carcinoma.
Because patients with hormone-refractory prostate carcinoma are a very diverse group, management of these patients represents a unique challenge. Despite much research, to the authors' knowledge few studies published to date have provided definitive treatment answers. The Society of Urologic Oncology (SUO) convened a multidisciplinary panel of urologists, oncologists, and radiation oncologists to develop a treatment algorithm for patients with hormone-refractory prostate carcinoma. The resulting treatment outline was based on a review of the literature review and on the expert opinions of the panelists. The current article provided a logical progression of treatment choices that included hormonal manipulations, chemotherapeutic options, and adjunctive therapies. Future clinical trials and therapies were also discussed by the authors. Management strategies should be targeted toward the individual patient. Although significant progress has been made in understanding and treating hormone-refractory prostate carcinoma, earlier interventions would be ideal and better therapeutic approaches to prolong survival are necessary.
Chang
Sam S
SS
Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA. sam.chang@vanderbilt.edu
Benson
Mitchell C
MC
Campbell
Steven C
SC
Crook
Juanita
J
Dreicer
Robert
R
Evans
Christopher P
CP
Hall
M Craig
MC
Higano
Celestia
C
Kelly
W Kevin
WK
Sartor
Oliver
O
Smith
Joseph A
JA
D000465:Algorithms; D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology* / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy* / Q000473:pathology; D002986:Clinical Trials as Topic; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008297:Male; D010166:Palliative Care; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D012955:Societies, Medical
D018931:Antineoplastic Agents, Hormonal